The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

By H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner. New England Journal of Medicine, 2001

3,254 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/bec1f00c2120232a55a25b7d846d63e92a3ff8fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Daniel Levy
2. Michael J. Pencina
3. Martin G. Larson
4. I. Neeland
5. D. Lloyd‐Jones
6. Ramachandran S. Vasan

In Endocrinology, Diabetes and Metabolism

1. Michael J. Pencina
2. S. Grundy

Citations in the corpus

• A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “171,172 175 Use of ACE inhibitors/ARBs and mineralo-corticoid receptor antagonists may be complicated in CKD because of concerns about hypotension, hyperkalemia, and worsening renal function.”
• Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. (2005, background): “proteinuria (a protein-to-creatinine ratio of 300 mg/g) can slow or prevent the progression of kidney disease [11, 12].”